Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine

Pharmacological Research

Volumn 39, Issue 4, 1999, Pages 289-295

  Sayed Ahmed, Mohamed M ^a   Shaarawy, Sabry ^b   Shouman, Samia A ^b   Osman, Abdel Moneim M ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Doxorubicin; Drug interaction; Fatty acid oxidation and cardiomyopathy; L carnitine

Indexed keywords

CARNITINE; CARNITINE PALMITOYLTRANSFERASE; DOXORUBICIN; ENOXIMONE; LONG CHAIN FATTY ACID COENZYME A LIGASE; PALMITIC ACID; PALMITOYL COENZYME A; PHOSPHODIESTERASE INHIBITOR;

ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; EHRLICH ASCITES TUMOR; ENZYME ACTIVITY; FATTY ACID OXIDATION; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0005792794     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0438     Document Type: Article

References (29)

1. Carter SK. Adriamycin - A review. J Natl Cancer Inst 1975; 55: 1265-74.
2. Kantrowitz NE, Bristow MR. Cardiotoxicity of anti-tumour agents. Prog Cardiovasc Dis 1984; 27: 195-200.
3. Buzadar AV, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985; 55: 2761-5.
4. Van Vleet J, Ferrans V, Weririch W. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol 1980; 99: 13-42.
5. Lefrak EA, Pitha J, Rosenhiem J, Gotibieb JH. Clinicopathological analysis of adriamycin cardiotoxicity. Cancer 32: 303-9.
6. Link G, Tirosh R, Pinson A, Hershko C. Role of iron in the protection of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron anthracycline interaction. J Lab Clin Med 1996; 127: 272-8.
7. Singal PK, Siveski-Iliskovic N, Hill M, Thomas PT, Li T. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 1995; 27: 1055-63.
8. Abdel-Aleem S, El-Merzabani MM, Sayed-Ahmed MM, Taylor DA, Lowe JE. Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol 1997; 29: 789-97.
9. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol 1974; 36: 413-59.
10. Bohles H, Noppeney T, Akcetin Z, Rein J, Vonder Emdey J. The effect of preoperative L-carnitine supplementation on myocardial metabolism during aorto-coronary bypass surgery. Curr Ther Res 1986; 39: 429-35.
11. Corr PB, Gross RS, Sobel BE. Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Cir Res 1985; 55: 135-54.
12. Van-Acker SA, Kramer K, Voest EE, Grimbergen JA, Zhang J, Van-der-Viigh WJ, Bast A. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors. Cancer Chemother Pharmacol 1996; 38: 95-101.
13. Osman AM, Al-Shabanuh OR, Al-Harbi MM, Al-Gharably NM, Aziz SA. Effect of desferrioxamine on doxorubcin-induced cardiac and hepatotoxicity in mice. Meel Sci Res 1993; 21(5): 193-4.
14. Mc Falls EO, Paulson DJ, Gilbert EF, Shug AL. Carnitine protection against adriamycin-induced cardiomyopathy in rats. Life Sci 1986; 38: 497-505.
15. i values for malonyl-CoA. J Biol Chem 1987; 262: 2050-5.
16. Frangakis CJ, Bahl JJ, McDaniel H, Bressler R. Tolerance to physiological calcium by isolated myocytes from the adult rat heart: An improved cellular preparation. Life Sci 1980; 27: 815-25.
17. Chappel JB, Hansford RG. In: Birnie GD, ed. Sub-Cellular Components, 2nd Ed. London: Butterworths, 1969: 77-91.
18. Yang S-Y, He X-Y, Schulz H. Fatty acid oxidation in rat brain is limited by the low activity of 3-ketoacyl-coenzyme A thiolase. J Biol Chem 1987; 262: 13027-32.
19. Abdel-Aleem S, Youssef J, Badr M, Frangakis CJ. The inhibition of long-chain fatty acyl-CoA synthetase by enoximone in rat heart mitochondria. J Cardiovasc Pharmacol 1992; 19: 899-904.
20. Osman AM, Sayed-Ahmed MM, Khayyal MT, El-Merzabani MM. Hyperthermic potentiation of cisplatin on solid Ehrlich carcinoma. Tumori 1993; 79: 268-72.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
22. Beanlands RSB, Shaikh NA, Wen W, Dawood F, Ugnat A, McLaaughlin PR, Carere R, Liu PP. Alteration in fatty acid metabolism in adriamycin cardiomyopathy. J Mol Cell Cardiol 1994; 26: 109-19.
23. Wakasugi S, Fischman AL, Babich JW, Callahan RJ, Elmaleh DR, Wilkinson R, Strauss HW. Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. J Nucl Med 1993; 34: 1529-35.
24. Sayed-Ahmed MM. Pharmacological and Biochemical Studies on the Mechanism(s) of Adriamycin-induced Cardiotoxicity. Ph.D. Thesis, Cairo University, Cairo, Egypt, 1995.
25. Abdel-Aleem S, Sayed-Ahmed MM, Nada MA, Hendrickson SC, Louis JS, Walthhall HP, James EL. Regulation of fatty acid oxidation by acetyl-CoA generated from glucose utilization in isolated myocytes. J Mol Cell Cardiol 1995; 28: 825-33.
26. Schulz H. Regulation of fatty acid oxidation in heart. J Nutr 1994; 124: 165-71.
27. Brady LJ, Brady PS. Hepatic and cardiac carnitine palmitoyltransferase activity. Effects of adriamycin and galactosamine. Biochem Pharmacol 1987; 36: 3419-23.
28. Kashfi K, Israel M, Sweatman TW, Seahadri R, Cook GA. Inhibition of mitochondrial carnitine palmitoyltransferase by adriamycin and adriamycin analogues. Biochem Biopharmacol 1990; 40: 1441-8.
29. Senekowitsch R, Lohninger A, Kriegel H, Staniek H, Krieglsteiner HB, Kaiser E. Protective effect of carnitine on adriamycin toxicity to heart disorders. Proc. Satell. Symp. ZAK, Graz. 1985: 126-137 (Karger, Basel 1987).